{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T02:49:07Z","timestamp":1783997347447,"version":"3.55.0"},"reference-count":48,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T00:00:00Z","timestamp":1739318400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec><jats:title>Aim<\/jats:title><jats:p>Vafidemstat is a brain\u2010penetrant, orally bioavailable, small molecule irreversible inhibitor of the histone lysine\u2010specific demethylase KDM1A (also known as LSD1), which corrects memory deficits and behavior alterations including aggression and social interaction deficits in preclinical models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Here, we report the results of REIMAGINE, a phase IIa, single\u2010center, open\u2010label, one\u2010arm basket trial that evaluated the safety and efficacy of vafidemstat on aggression in adult patients with borderline personality disorder (BPD), attention\u2010deficit\/hyperactivity disorder (ADHD), and autistic spectrum disorder (ASD). Participants received 1.2 mg\/day of vafidemstat for 8\u2009weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Vafidemstat was shown to be safe and well tolerated, and no drug\u2010related clinically significant adverse events were observed. Furthermore, all neuropsychiatric scales assessed showed notable efficacy signals, whether assessing agitation\/aggression (Clinical Global Impression for Severity [CGI\u2010S] and Clinical Global Impression for Improvement [CGI\u2010I] and Neuropsychiatric Inventory [NPI] questionnaire for Agitation\u2010Aggression [NPI\u2010AA]), overall patient functioning (total NPI), or disease\u2010specific features (Attention\u2010Deficit\/Hyperactivity Disorder Rating Scale [ADHD\u2010RS] and Borderline Personality Disorder Checklist [BPDCL]). Statistically significant improvements were observed in the aggregated data (all participants) and for each of the three disease groups independently. Changes were evident within the first 2\u2009weeks of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In summary, the REIMAGINE study supports that vafidemstat is safe, well tolerated, and causes a significant and consistent reduction in agitation\/aggression and nonaggression features in BPD, ADHD, and ASD. These data support continuing the development of vafidemstat as a new treatment option for these psychiatric disorders.<\/jats:p><\/jats:sec>","DOI":"10.1111\/pcn.13800","type":"journal-article","created":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T13:30:43Z","timestamp":1739367043000},"page":"257-265","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["REIMAGINE: A central nervous system basket trial showing safety and efficacy of vafidemstat on aggression in different psychiatric disorders"],"prefix":"10.1111","volume":"79","author":[{"given":"Marc","family":"Ferrer","sequence":"first","affiliation":[{"name":"Department of Psychiatry Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Richarte","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Gisbert","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6896-8814","authenticated-orcid":false,"given":"Jordi","family":"Xaus","sequence":"additional","affiliation":[{"name":"Oryzon Genomics S.A. Cornell\u00e0 de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Oryzon Genomics S.A. Cornell\u00e0 de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Isabel","family":"Arevalo","sequence":"additional","affiliation":[{"name":"Oryzon Genomics S.A. Cornell\u00e0 de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ropacki","sequence":"additional","affiliation":[{"name":"Oryzon Genomics S.A. Cornell\u00e0 de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Bullock","sequence":"additional","affiliation":[{"name":"Oryzon Genomics S.A. Cornell\u00e0 de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Buesa","sequence":"additional","affiliation":[{"name":"Oryzon Genomics S.A. Cornell\u00e0 de Llobregat  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep Antoni","family":"Ramos\u2010Quiroga","sequence":"additional","affiliation":[{"name":"Department of Psychiatry Hospital Universitari Vall d'Hebron  Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,2,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.59.8433"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn.4399"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddl013"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-244X-13-213"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10110"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2013.03.030"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2019.09.014"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0233468"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14071420"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v69n0404"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2006.09.019"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2009.08121825"},{"key":"e_1_2_8_14_1","first-page":"129","volume-title":"Textbook of Personality Disorders","author":"Torgersen J","year":"2005"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.156.5.733"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1053\/comp.2001.26271"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.163.1.20"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12402-016-0208-3"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1089\/cap.2015.0126"},{"key":"e_1_2_8_20_1","first-page":"389","article-title":"Treatment of adults with attention\u2010deficit\/hyperactivity disorder","volume":"4","author":"Kolar D","year":"2008","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-010-1118-4"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/070674371205700502"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI32483"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/0706743716689055"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-019-2377-z"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1177\/00912174231166252"},{"key":"e_1_2_8_27_1","unstructured":"EU Clinical Trials Register.eudract 2018\u2010002140\u201088. an unicenter open\u2010label 1\u2010arm 8\u2010week study to evaluate the efficacy safety and tolerability of ORY\u20102001 in aggression in adult population with adult attention deficit hyperactivity disorder (ADHD) borderline personality disorder (BPD) autism spectrum disorder (ASD) (REIMAGINE).2018. [Cited 13 October 2021.] Available from URL:https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2018-002140-88\/ES."},{"key":"e_1_2_8_28_1","unstructured":"World Health Organization.The use of the WHO\u2010UMC system for standardised case causality assessment.2013. [Cited 4 January 2022.] Available from URL:https:\/\/www.who.int\/publications\/m\/item\/WHO-causality-assessment."},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.books.9781615377268.lg04"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2011.10111704"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.48.5_Suppl_6.10S"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpsm.2017.06.003"},{"key":"e_1_2_8_33_1","first-page":"281","article-title":"The borderline personality disorder checklist: Psychometric evaluation and factorial structure in clinical and nonclinical samples","volume":"20","author":"Bloo J","year":"2017","journal-title":"Rocz. Psychol."},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpsy.2017.08.003"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.RA118.006980"},{"key":"e_1_2_8_36_1","article-title":"Direct measurement of KDM1A target engagement using chemoprobe\u2010based immunoassays","volume":"148","author":"Mascar\u00f3 C","year":"2019","journal-title":"J. Vis. Exp."},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1080\/23262133.2016.1249195"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/cercor\/bhr218"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2015.01.010"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40291-022-00609-y"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2020.00579"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnhum.2022.955005"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.02.011"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-018-0300-9"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-021-01233-w"},{"key":"e_1_2_8_46_1","first-page":"103","article-title":"NMDA neurotransmission as a critical mediator of borderline personality disorder","volume":"32","author":"Grosjean B","year":"2007","journal-title":"J. Psychiatry Neurosci."},{"key":"e_1_2_8_47_1","unstructured":"EU Clinical Trials Register.EUDRACT 2020\u2010003469\u201020. A double blind randomized placebo\u2010controlled adaptive 14\u2010week Phase IIb trial to evaluate the efficacy and safety of vafidemstat in an adult borderline personality disorder (BPD) population (PORTICO).2020. [Cited 19 October 2021.] Available from URL:https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2020-003469-20\/ES."},{"key":"e_1_2_8_48_1","unstructured":"US National Clinical Trial Register.Study to test the efficacy and safety of vafidemstat in adult borderline personality disorder population.2021. [Cited 20 May 2022.] Available from URL:https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04932291."},{"key":"e_1_2_8_49_1","unstructured":"EU Clinical Trials Register.Eudract 2021\u2010000350\u201026. a double\u2010blind randomized placebo\u2010controlled adaptive 24\u2010week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia (EVOLUTION).2021. [Cited 19 October 2021.] Available from URL:https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/trial\/2021-000350-26\/ES."}],"container-title":["Psychiatry and Clinical Neurosciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/pcn.13800","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:59:14Z","timestamp":1746190754000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/pcn.13800"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,12]]},"references-count":48,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["10.1111\/pcn.13800"],"URL":"https:\/\/doi.org\/10.1111\/pcn.13800","archive":["Portico"],"relation":{},"ISSN":["1323-1316","1440-1819"],"issn-type":[{"value":"1323-1316","type":"print"},{"value":"1440-1819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,12]]},"assertion":[{"value":"2024-09-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}